Thomas E Delea
8PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Aug 04, 2024
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population.Thomas E Delea, Qiufei Ma, Glenn S Kroog
|Jul 17, 2021
Lifetime Costs for Treated Follicular Lymphoma Patients in the US.Caitlin Eichten, Qiufei Ma, Thomas E Delea
|Jun 09, 2021
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.Daniel Stellato, Marroon E Thabane, Jinhee Park
|May 18, 2021
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2- Advanced Breast Cancer: A Canadian Healthcare Perspective.Daniel Stellato, Marroon E Thabane, David Chandiwana
|Feb 01, 2021
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA.Deepu Madduri, May Hagiwara, Kejal Parikh
|Jun 21, 2019
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.Thomas E Delea, Xinke Zhang, Jordan Amdahl
Pageof 2
